Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million before expenses [1][2]. Group 1: Offering Details - The public offering consists entirely of shares sold by the Company, with underwriters granted a 30-day option to purchase an additional 5,217,391 shares [2]. - The Offering is expected to close on January 22, 2026, pending customary closing conditions [1]. - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, contingent on the completion of the public offering [3]. - The private placement will require a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the Offering and the Private Placement will support the growth and clinical strategy of the Company, including the DurAVR Transcatheter Heart Valve global pivotal trial [4]. - Funds will also be allocated to expand manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining proceeds for working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is focused on developing innovative medical devices for heart function restoration, with a significant presence in both Australia and the USA [10]. - The lead product, DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [11].

Core Viewpoint - Picard Medical, Inc. has entered into a development collaboration agreement with Hydrix Services Pty Ltd to advance the next-generation fully implantable Total Artificial Heart technology, known as the Emperor, which aims to enhance patient mobility and convenience by eliminating the need for an external driver [1][2]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is recognized for developing the only commercially available total artificial heart technology for patients with end-stage heart failure [5]. - SynCardia's Total Artificial Heart (STAH) is the first artificial heart approved by both the U.S. FDA and Health Canada, with over 2,100 implants performed across 27 countries, making it the most widely used artificial heart globally [5]. Collaboration Details - The partnership with Hydrix was chosen due to its expertise in complex critical engineering and a strong track record in developing regulated medical devices, particularly mechanical circulatory support systems [2]. - The development work under this agreement will continue through the end of 2026 as part of a broader multi-stage program, with progress contingent on technical performance and safety validation [3]. Financial Incentives - The collaboration may allow Picard to benefit from Australian R&D tax incentives of approximately 43% of eligible expenditure, subject to qualification and review [3]. Hydrix Overview - Hydrix Limited is a product innovation company focused on enhancing health and well-being through its services in design, engineering, and delivery of medical products, as well as investing in high-potential MedTech clients [4].

As filed with the U.S. Securities and Exchange Commission on December 18, 2025. Registration No. 333- (State or other jurisdiction of incorporation or organization) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Number) Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear ...

As filed with the U.S. Securities and Exchange Commission on October 17, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3842 86-1369123 (Primary Standard Industrial Classification Code Number) (IRS Employer Identification Number) 4875 White Bear P ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on January 26, 2023 Registration Statement No. 333-269207 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) 3841 (Primary Standard Industrial Classification Code Number) 26-1828101 (I.R.S. Employer Identification Number) 1001 Calle Amanecer San Clem ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on January 12, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 26-1828101 (I.R.S. Employer Iden ...